cryoprotectant solutions to form the liposome suspensions. The effects of different concentrations of SPC on the encapsulation efficiency (EE%) of SBS are shown in Fig. 1 .
Lyophilization of Liposomes Lyophilization of liposome suspensions was performed for 48 h using different kinds of cryoprotectants, i.e. glucose, mannitol, trehalose or lactose. The liposome suspensions with different mass ratios of SPC to each kind of cryoprotectant (1 : 1 to 1 : 6) were frozen at Ϫ20°C first. Then the frozen liposome suspensions were put into the freeze-dryer (Labconco, Freezezone 6, U.S.A.) for 48 h to yield the lyophilized liposomal powders. The temperature of the freeze-dryer was Ϫ50°C and the vacuum was below 133ϫ10 Ϫ3 mBar. The encapsulation efficiencies of SBS following the dehydration rehydration cycle were determined. The results are shown in Table 1 .
Development of Liposomal Dry Powder Inhaler Formulations First, the formulations with different kinds of cryoprotectants were prepared to investigate the effect of cryoprotectant on the in vitro deposition profiles of SBS. Under the most optimal mass ratio of SPC to cryoprotectant according to Table 1 , lyophilization of liposomes with different kinds of cryoprotectants (glucose, mannitol, trehalose or lactose) was performed, and the resulting porous cakes were sieved through 400-mesh sieves manually. Then, the different kinds of sieved lyophilized liposomal powders were mixed with coarse lactose carriers (63-106 mm sieved alphalactose monohydrate) in the mass ratio of 1 : 5, respectively. Capsules (size 2) were filled with 200 mg dry powder (containing 1000Ϯ50 mg SBS). Finally, in vitro deposition studies of these four kinds of formulations were performed using a twin-stage impinger (TSI) (Apparatus A, British Pharmacopoeia). The fine particle fraction (FPF) of SBS was determined for each kind of formulation. The results are shown in Table 2 .
Next, the effects of different amounts of coarse lactose (63-106 mm) as carrier on the deposition performance of inhalers were also investigated. According to the results in Table 2 , lactose was selected as the appropriate cryoprotectant among these four kinds of sugars. The process of preparation was similar to that described above except that different mass ratios of sieved lyophilized liposomal powders to coarse lactose carrier (1 : 1 to 1 : 7) were used. The FPF of SBS was determined for each kind of formulation. The results are shown in Table 3 .
Furthermore, the effect of magnesium stearate on deposition performance of the inhalers was also investigated. Magnesium stearate (0.5%) was added as a lubricator to the selected formulation. The process of preparation was similar to that described above except that 0.5% magnesium stearate was mixed with the coarse lactose carrier (63-106 mm sieved alpha-lactose monohydrate).
Finally, the powder selected according to the above experiments was crushed by ball milling (qm-1sp2, Equipment Company of Nanjing University, China) and sieved through a 400-mesh sieve mechanically (Sieve shaker with Sieves, Fritsch, analysette 3PRO, Germany) to control the particle size of the powders. The rotation speed of the ball mill was set at 77 rpm and the milling time was 1 h. The sieving time was 10 min and the amplitude was 2.0 mm. The particle size of this kind of powder was determined using a Beckman Coulter LS 13 320 Series Laser Diffraction Particle Size An- The mass ratio of liposome powder to carrier lactose was 1 : 5. a) MeanϮS.D., nϭ3. alyzer before and after the ball milling. A deposition study was also performed. The results are shown in Table 4 . Determination of SBS Encapsulation Efficiency in Liposomes A Microcon ® centrifugal filter device containing an ultrafiltration membrane (NMWL 10000, Millipore, U.S.A.) was used to determine the encapsulation efficiency of SBS. An aliquot of 200 ml of the liposome suspension was added to the sample reservoir and centrifuged (Avanti ® J-E, Beckman Coulter, U.S.A.) for 15 min at 17400ϫg, 6°C. Fifty microliters of filtrate was diluted with 1450 ml of ethanol and was assayed to determine the concentrations of the unencapsulated SBS by a UV spectrophotometer Model Cary 50 Tablet UV-Visible system (Varian Technologies Asia Ltd., Taiwan Branch) at 276 nm. Liposome structure was destroyed by adding ethanol: 1450 ml ethanol was added to 50 ml of the original liposome suspension and this released SBS for the determination of total SBS. Encapsulation efficiency was calculated by the following formula:
Determination of Fine Particle Fraction
A twin-stage impinger (TSI, British Pharmacopoeia) was used to evaluate the in vitro deposition profiles of SBS. The volumes of capturing solvent (water) in the upper (stage 1) and lower (stage 2) impingement chambers were 7 ml and 30 ml, respectively. A spinhaler was used as a delivery device at a flow rate of 60Ϯ5 l/min for 5 s for 10 capsules. The inner surface of the inlet tube to the lower impingement chamber and the surface that projects into the chamber were washed with water; the washings from the lower impingement chamber were collected. The contents of SBS in the collected washings were determined. An HPLC system (Alltech 1100 Series, U.S.A.) was used to determine the concentrations of SBS with a diode array detector (DAD) at 276 nm. A 25 cmϫ4.6 mm C18 column (Phenomenex, Torrance, CA, U.S.A.) was used. The mobile phase consisted of acetonitrile : water (10 : 90) with sodium dihydrogen phosphate 30 mmol/l. The mobile phase was adjusted to pH 3.5 with 1.0 M phosphoric acid. The flow rate was 1.0 ml/min. The column temperature was 25°C. The amounts of SBS collected in the lower impingement chamber per discharge were calculated, and the results were expressed as a percentage (FPF) of the actual dose. Transmission Electron Microscopy (TEM) The mor-phology of the liposomes before lyophilization was examined by transmission electron microscopy (EM208s, PHILIPS) using a negative staining technique employing a 2% uranyl acetate solution. Scanning Electron Microscopy (SEM) The surface morphology of powders before and after ball milling were viewed and photographed by scanning electron microscopy (S-4800, Hitachi) after the powders were coated by gold (SCD 005 Sputter Coater, BAL-TEC).
Determination of Angle of Repose
In Vitro Release of Liposomes An in vitro release study of the VPG liposome suspension was performed by using a dialysis bag method. The dissolution medium was 300 ml deionized water and the temperature of the dissolution medium was kept at 37°C. An aliquot of 9 ml VPG liposome suspension (SBS: 10.1 mg/ml; SPC: 40.5 mg/ml; SBS encapsulation efficiency: 80.1%) inside the dialysis bag (NMWL 12000) was dipped into 300 ml of deionized water. The dissolution medium was stirred continuously during the release study. During the study, 3 ml of dissolution medium was withdrawn at predetermined time intervals. An equal volume of release medium was replaced after each withdrawal. To compare the speed of free SBS permeating the dialysis bag, an aliquot of 9 ml of free SBS solution (SBS: 10.1 mg/ml) was used as the control to perform an in vitro release study similar to that described above. The concentration of SBS was determined by the UV spectrophotometer Model Cary 50 Tablet UV-Visible system (Varian Technologies Asia Ltd., Taiwan Branch) at 276 nm. According to the determined concentrations of released SBS and total SBS, the profile of SBS released from the VPG liposome suspension was drawn after deducting the amounts of original free SBS outside the liposomes at each time point. The release profile of SBS is shown as Fig. 2 .
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Fig. 2. SBS Release Profile of the Dissolution Test
The concentration of SBS was 10.1 mg/ml in both free drug solution and liposomal drug suspension. Free SBS solution (--), liposomal SBS suspension (-᭜-). The results are presented as the meanϮS.D., nϭ3. The mass ratio of liposome powder to carrier lactose was 1 : 5 and 0.5% magnesium stearate as lubricator. a) MeanϮS.D., nϭ3.
RESULTS AND DISCUSSION

Selection of SPC Concentration in VPG Liposomes
In order to investigate the effect of SPC content on encapsulation efficiency of SBS in VPG liposome suspensions, a series of SPC dispersions was prepared with increasing SPC content, from 250 to 500 mg/g. As shown in Fig. 1 , the encapsulation efficiency of SBS rose together with an increase in SPC content. The reason for the rise of encapsulation efficiency of SBS with an increase in SPC content may be explained as follows: during the dilution of VPG with aqueous medium, the VPG were transformed into dispersed and separated vesicles. The fraction of drug trapped in the core of the vesicles stayed entrapped, while the fraction of drug which had been present in the aqueous space between the vesicles was released. The encapsulation efficiency for SBS was thus determined by the ratio of vesicle core volume compared to overall aqueous space within the original VPG. Thus, the encapsulation efficiency of SBS increased with increasing SPC concentrations from 250 to 400 mg/g. However, there was little increase in efficiency above 400 mg/g. This may be due to the fact that the vesicles of liposomes might be close to maximum density sphere packing of the liposome preparation taken up by the vesicles when the content of SPC increased to 400 mg/g and the aqueous core of these vesicles might also approach the maximum of the total volume of all aqueous compartments. 13, 14) Thus, there was only a slight increase in encapsulation efficiency when the content of SPC increased from 400 to 500 mg/g. Therefore, we selected the SPC concentration of 400 mg/g for the subsequent studies including the inhaler test.
The morphology of the liposomes (hydrated by deionized water from VPG of 400 mg/g) before lyophilization is shown in Fig. 3 . From the micrograph it can be seen that the small unilamellar vesicle (SUV) liposomes were formed and the particle size was approximately 100-200 nm.
Selection of Cryoprotectants The prepared VPG liposomes were lyophilized using different kinds of cryoprotectants. In our study, we also determined different sugars performed optimally in different amounts. As shown in Table 1 , the structure of liposomes was best preserved by using lactose as a cryoprotectant in the mass ratio 1 : 4 of SPC to lac-tose. At this ratio, the encapsulation efficiency of SBS was 80.71Ϯ2.55% before lyophilization and 44.35Ϯ1.11% after dehydration rehydration. Therefore, we selected lactose as the cryoprotectant and this ratio for the subsequent studies. Meanwhile, HPLC was used to determine the SBS content of this selected lyophilized powder before and after sieving. The results showed that the SBS content was almost the same between before and after sieving the sample (RSD% Ͻ2%). This indicated that the drug content was uniform in lyophilized powder. The ability of lactose and other kinds of cryoprotectants to preserve the structural and functional integrity of liposomes during hydration was mainly due to their structures. Hydration of liposome polar head groups with the hydroxyl groups of cryoprotectant leads to the stabilization of liposomes. If the concentration of cryoprotectant was less than optimal, the cryoprotectant crystals cannot provide adequate surface area for the adherence of the condensed liposome bilayer, and leakage of drug from the liposomes occurs. Hence, the optimal concentration of sugar required as cryoprotectant depended on the saturation of the polar head groups of the liposome bilayer by drug or other formulation components and this would vary with the type of cryoprotectant used. Meanwhile, during dehydration, sugars that acted as cryoprotectants protected the liposomal permeability barrier. This can reduce the leakage of SBS from the liposomes. [15] [16] [17] When the content of SPC was 400 mg/g, the encapsulation efficiency of liposome suspension hydrated by lactose solution (mass ratio of SPC to lactose was 1 : 4) was 80.71Ϯ 2.55% (Table 1 ). This was much higher than that of the liposome suspension hydrated by deionized water (57.26Ϯ 1.02%) (Fig. 1 ). This can further confirm that cryoprotectants can preserve the structural and functional integrity of liposomes during hydration.
The particle sizes of liposomes (different amounts of lactose were used as cryoprotectant) before and after lyophilization are listed in Table 5 . The results showed that the particle sizes of liposomes before lyophilization were approximately 100-200 nm, which were in accordance with the results of TEM (Fig. 3) .
In Vitro Release An in vitro SBS release study of the VPG liposome suspension was also performed. Figure 2 shows the release profile of SBS from the liposomes. The results showed that SBS was sustained in release from the liposomes. The release of SBS from the liposomes lasted for 24 h. However, only 1.5 h were needed for free SBS to be released from the dialysis bag to the medium when the concentration and volume of free SBS solution was equal to the liposome suspension. The results indicated that SBS entrapped in the liposomes was released gradually and evenly from the liposomes. Table 2 shows the angle of repose of each kind of formulation and the effect of different kinds of cryoprotectants used in lyophilized liposomal powders on FPF. The flowability of the dry powders was an important factor affecting its in vitro deposition performance. The results showed that the angle of repose (41.4Ϯ0.95°) of the formulation containing lactose as cryoprotectant was the smallest among these four kinds of cryoprotectants, indicating that its flowability was better than the other formulations. Since the highest FPF value (6.34Ϯ0.98%) found in lactose (Table 2 ) and the structure of liposomes was best preserved by using lactose as cryoprotectant in the mass ratio 1 : 4 of SPC to lactose (Table 1) , it was chosen as the cryoprotectant for subsequent studies.
Development of Liposomal Dry Powder Inhaler Formulations
Magnesium stearate was another substance that, when added to dry powder inhalers, can improve their performance. 18) We found that when magnesium stearate at 0.5% (w/w) was added to the selected formulation which contained lactose as cryoprotectant according to Table 2 , the angle of repose decreased from 41.4Ϯ0.95 to 38.9Ϯ0.89°, and the FPF value of SBS increased from 6.34Ϯ0.98 to 16.26Ϯ 0.51%, indicating that magnesium stearate was a valuable addition. This benefit of adding magnesium stearate to the formulation was sometimes questioned due to the potential risk associated with delivery of this agent deep into the lungs. However, Guchardi et al. reported that 0.5% magnesium stearate added to the formulation had no negative effect in toxicological studies. Therefore, the benefit of using magnesium stearate was greater than the perceived risks. 18) Thus, 0.5% magnesium stearate was chosen as the lubricator for subsequent studies.
Different mass ratios of lactose (63-106 mm) were used as the carrier to formulate our liposomal SBS dry powder inhalers. The lyophilized liposome powders were mixed with lactose carrier in the range of mass ratio from 1 : 1 to 1 : 7. Table 3 shows that the FPF of SBS for a mass ratio of 1 : 5 was higher than other ratios; thus, we concluded that the optimum mass ratio of lyophilized powders to carrier was 1 : 5. These results showed that the amount of lactose carrier affects FPF, and that an optimum amount of carrier was required to achieve an optimum in vitro deposition performance of liposomal dry powders. Table 4 presents the effects of ball mill processing on the particle size and SBS FPF of liposomal SBS dry powders. After being crushed by a ball mill and sieved through a 400-mesh sieve by sieve shaker, the mean particle size of liposomal SBS dry powders decreased from 40.21Ϯ3.25 to 9.84Ϯ2.75 mm. Meanwhile, FPF of SBS increased from 16.26Ϯ0.51 to 41.51Ϯ2.22%. This indicated that the particle size of liposomal SBS dry powder was an important factor determining the FPF of SBS. Figure 4 shows the surface morphology, examined by SEM, of the optimal dry powder formulation (the content of SPC in VPGs was 400 mg/g; using lactose as the cryoprotectant, the mass ratio of lyophilized powders to carrier was 1 : 5, using 0.5% magnesium stearate as the lubricator and the powders were crushed by the ball mill and sieved through the 400-mesh sieve by sieve shaker) before and after ball milling. Figures 4A1 and B1 show the surface morphology of the dry powders before and after ball milling at ϫ1000 magnification, respectively. An obvious difference can be observed between these two kinds of powders. The particle size of the dry powder before ball milling (40.21Ϯ3.25 nm) was much larger than that (9.84Ϯ2.75 nm) after ball milling. Figures 4A2 and B2 show the surface morphology of the dry powders before and after ball milling at ϫ50000 magnification, respectively. The shapes of liposomes can be clearly observed and the particle sizes of liposomes were less than 500 nm.
Finally, the encapsulation efficiency of the developed formulation of liposomal dry powder according to the above experiments was determined. It was found that this encapsulation efficiency (31.39Ϯ3.37%) was lower than that of lyophilized liposomal powders after dehydration rehydration (44.35Ϯ1.11%). This might be due to the fact that during the process of liposomal SBS dry powder preparation, the mechanical process of sieving and ball milling could partially destroy the structural integrity of the SBS liposomes, which would result in the decrease of encapsulation efficiency of SBS. The results indicated that about 13% of liposomal SBS can be effectively delivered to the lung in our design formulation.
In conclusion, VPG SBS liposomes of high encapsulation efficiency (more than 80%) were successfully prepared and stabilized by lyophilization into dry powder formulations for asthmatic inhalers in this study. The developed formulation of liposomal dry powder was obtained (the content of SPC in VPG was 400 mg/g; using lactose as the cryoprotectant, the mass ratio of lyophilized powders to carrier was 1 : 5, using 0.5% magnesium stearate as the lubricator and the powders were crushed by ball milling and passed through a 400-mesh sieve by sieve shaker). An in vitro deposition study of this new liposomal SBS dry powder inhaler showed that 13% of liposomal SBS could be effectively delivered to the lung. Moreover, sustained release of SBS entrapped by liposomes was achieved. The results of this study suggest the promising possibility of localized pulmonary liposomal SBS delivery in the anhydrous state. 
